Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 377

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 377
---
            |    301 |     |             |    301 |     | $         | 3.00 |     |          |    580 |     |             |    903 |
| Series C    |     |                         | 8/29/2023  |     |            | 75,000 |     |             | 47,154 |     | $         | 1.50 |     |          | 68,773 |     |             | 70,731 |
|             |     |                         |            |     |            | 79,251 |     |             | 51,405 |     |           |      |     | $        | 75,967 |     | $           | 80,484 |

In August 2023, the Company closed the Series C Offering with four new investor groups (“Series C New Investors”) to invest $75.0 million of which $35.0 million was payable upon the first closing in August 2023 and $40.0 million payable upon the enrollment of the first patient into the Phase 2 trial of LB-102.The second closing occurred in January 2024. The Company issued 23.3 million and 26.7 million shares of Series C preferred stock at the first and second closings, respectively. In conjunction with the Series C Offering, the strike price of warrants held by Series A and Series B preferred stockholders was reduced to $0.01 per share and the Series B preferred stockholders received 100,373 newly issued warrants at a strike price of $1.50 (“New Series B Warrants”), allowing the Series B preferred stockholders to purchase common stock in an amount equal to one-thirdof their current Series B preferred stock. See Warrants section below for additional information. The Company incurred issuance costs of $2.0 million associated with the Series C preferred stock and New Series B Warrants. Upon the closing of the Series C Offering, the 2020 Notes and 2022 Notes automatically converted to 23.8 million shares of Series C preferred stock at a price of $1.50 per share. See Note 11 Notesfor additional information. As of December 31, 2024, the holders of the Preferred Stock have the following rights and preferences: Voting: The holders of the Preferred Stock shall have full voting rights and powers and shall vote together with all other classes and series of stock of the Company. Each holder of Preferred Stock shall be entitled to the number of